Aurobindo Pharma, Glenmark and 1 other recall products in US market over production issue: USFDA
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-08-27 07:00 GMT | Update On 2024-08-27 07:00 GMT
Advertisement
New Delhi: Aurobindo Pharma, Glenmark, and FDC Ltd. are recalling certain products in the United States over manufacturing issues, according to the US Food and Drug Administration (USFDA).
A unit of Hyderabad-based based company, Aurobindo Pharma USA Inc. is recalling 240 bottles of pain-relieving medication Healthy Living Acetaminophen, Aspirin (NSAID) and caffeine tablets.
As per the latest enforcement report of USFDA, the company is recalling the affected lot due to "Missing Label".
Some bottles are missing the manufacturer's label that includes the drug facts information, the US health regulator said.
The New Jersey-based Aurobindo Pharma USA Inc initiated the Class 1 recall on July 11, it said.
As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems.
Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, produced at a Madhya Pradesh plant, due to "Failed Dissolution Specifications", USFDA said.
Glenmark Pharmaceuticals Inc, USA initiated the Class II recall on July 31, it added.
According to PTI, USFDA report said Maharashtra-based drug maker FDC Ltd is recalling 176,784 bottles of Timolol Maleate Ophthalmic Solution USP due to "Defective Container".
Patients are unable to get the solution out of the bottle as the spike of the cap is lodged in the nozzle of the product bottle, it said.
The company initiated the Class II recall August 12 this year.
As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.